The DLAT Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the DLAT gene has been disrupted in the A-549 human lung adenocarcinoma line. This polyclonal model provides a heterogeneous loss-of-function system for studying DLAT-dependent metabolic processes without clonal selection artifacts. The knockout eliminates the dihydrolipoamide S-acetyltransferase (E2) component of the pyruvate dehydrogenase complex, offering a robust tool for investigating mitochondrial metabolism and tumor cell biology.
A-549 cells originate from a human lung carcinoma and are a classic model of alveolar type II pneumocytes. They exhibit epithelial morphology and tumorigenic properties, widely used to study lung adenocarcinoma biology, drug metabolism, and respiratory toxicology. Their rapid proliferation and metabolic plasticity make them ideal for probing the interplay between mitochondrial function and cancer cell fitness, particularly in the context of metabolic reprogramming.
DLAT encodes the E2 subunit of the pyruvate dehydrogenase complex (PDC), which converts pyruvate to acetyl-CoA, linking glycolysis to the TCA cycle. PDC activity is tightly regulated: pyruvate dehydrogenase kinases (PDK1?C4) phosphorylate and inhibit the E1?? subunit, while pyruvate dehydrogenase phosphatases (PDP1/2) reverse this. Upstream signals from insulin, PGC-1??, HIF-1??, and FOXO1 modulate PDK and PDP expression. DLAT interacts with PDHA1, PDHB, DLD, and the E3 binding protein within the PDC. DLAT-mediated acetyl-CoA production is essential for TCA cycle flux, ATP synthesis, and histone acetylation; its loss forces cells to rely on glycolysis and glutamine metabolism, altering cellular energetics and redox balance.
In A-549 lung adenocarcinoma cells, DLAT knockout ablates PDC activity, impairing mitochondrial respiration and inducing a glycolytic shift characteristic of the Warburg effect. This metabolic reprogramming impacts cell proliferation, apoptosis, and sensitivity to chemotherapeutics. The model is pertinent to studying pyruvate dehydrogenase deficiency, Leigh syndrome, and metabolic adaptations in lung cancer. It enables dissection of how mitochondrial dysfunction drives tumor progression and reveals therapeutic vulnerabilities in non-small-cell lung carcinoma.
This DLAT knockout polyclonal population supports a broad range of investigations, including cancer metabolism, drug resistance, and mitochondrial dysfunction. Common assays include Seahorse metabolic flux analysis, PDH activity assays, immunoblotting for DLAT and pathway proteins, and LC-MS metabolomics to monitor TCA cycle intermediates. Cell proliferation, apoptosis, colony formation, and drug sensitivity testing can be coupled with these readouts to evaluate functional outcomes. The product is suitable for both mechanistic studies and high-throughput screening. For further inquiries, please contact Ascent Research.
